Cart
sales@molnova.com
p53 17-26
CAS No. 488118-64-5
p53 17-26( —— )
Catalog No. M30492 CAS No. 488118-64-5
This peptide is amino acids 17 to 26 fragment of p53, the Mdm-2 binding domain of p53 known also as p53N. This sequence contains all of the residues that contact the binding domain of Mdm-2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Namep53 17-26
-
NoteResearch use only, not for human use.
-
Brief DescriptionThis peptide is amino acids 17 to 26 fragment of p53, the Mdm-2 binding domain of p53 known also as p53N. This sequence contains all of the residues that contact the binding domain of Mdm-2.
-
DescriptionThis peptide is amino acids 17 to 26 fragment of p53, the Mdm-2 binding domain of p53 known also as p53N. This sequence contains all of the residues that contact the binding domain of Mdm-2.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetMDM2-p53
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number488118-64-5
-
Formula Weight1251.43
-
Molecular FormulaC60H90N12O17
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:{Glu}{Thr}{Phe}{Ser}{Asp}{Leu}{Trp}{Lys}{Leu}{Leu}
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Michl J, et al. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer. 2006 Oct 1;119(7):1577-85.
molnova catalog
related products
-
MS7972
MS7972 is a small molecules that blocks p53 and CREB binding protein (CBP) association.
-
SAR-405838
SAR-405838(MI-77301, MI-773) is a potent and highly selective small-molecule inhibitor of MDM2-p53 interaction with Ki of 0.88 nM.
-
DIMP53-1
A novel small-molecule dual inhibitor of p53-MDM2/X interactions by potentially binding to p53.
